• KSBB Journal
• /
• 제24권6호
• /
• pp.533-540
• /
• 2009

본 연구에서는 난용성 약물인 5'-NIO의 가용화를 위해 초임계 유체 ASES 공정을 이용하여 PVP K-30과의 고체분산체를 제조하고 첨가제인 P188의 영향에 대해 고찰하였다. FE-SEM을 이용하여 초임계 유체 공정으로 제조된 고체분산체 미립자의 형상을 분석한 결과 100-200 nm 크기의 나노입자들이 응집된 형태를 나타내었으며, P188의 함량이 증가함에 따라 입자간의 응집이 증가하여 덩어리 형태로 전환되는 것을 확인할 수 있었다. XRD 분석 결과 5'-NIO 결정피크가 사라진 것을 확인하였으며, 이는 5'-NIO가 고분자 매질내에 분자 또는 나노 크기 수준으로 분산되었음을 의미한다. 또한 FT-IR 분석 결과 5'-NIO와 PVP K-30간에 수소결합과 같은 상호작용이 존재함을 학인할 수 있었다. 5'-NIO/PVP K-30 2성분계 고체분산체에 비이온성 계면활성제를 첨가한 경우 용출률이 현저히 향상되었으나, P188의 함량이 매우 큰 경우에는 오히려 용출률이 감소한 다는 것을 확인하였다. 본 연구를 통해 초임계 유체 공정이 기존의 고체분산체 제조 방법을 충분히 대체할 수 있다는 가능성을 확인할 수 있었다.

• Journal of Pharmaceutical Investigation
• /
• 제25권1호
• /
• pp.31-36
• /
• 1995

Solid dispersions and inclusion complex were prepared for the enhancement of solubility and dissolution rate of poorly water-soluble ibuprofen(IPF) as a model drug. Polyethylene glycol 4000(PEG4000) and polyvinylpyrrolidone(PVP) were used for the preparation of solid dispersion. $2-Hydroxypropyl-{\beta}-cyclodextrin(2-HP{\beta}CD)$ was also used for the preparation of inclusion complex. The solubility of IPF increased as the concentration of PEG4000, PVP and $2-HP{\beta}CD$ increased. Solubilization capacity of $2-HP{\beta}CD$ was increased about 10 times when compared to PEG 4000 and PVP. The dissolution rate of drug from solid dispersions and inclusion complex in the simulated gastric fluid was enhanced when compared to pure IPF and commercial $BR4^{\circledR}$ tablet as a result of improvement of solubility. In case of solid dispersions, dissolution rate of drug was proportional to polymer concentration in the formulation. The marked enhancement of dissolution rate of drug by inclusion complexation with $2-HP{\beta}CD$ was noted. However, dissolution rate of drug from solid dispersions and inclusion complex in the simulated intestinal fluid was not significant because IPF was readily soluble in that condition. From these findings, water-soluble polymers and cyclodextrin were useful to improve solubility and dissolution rate of poorly water-soluble drugs. However, easiness and reliability of preparation method, scale-up and cost of raw materials must be considered for the practical application of solid dispersion and inclusion complex in pharmaceutical industry.

• Journal of Pharmaceutical Investigation
• /
• 제37권1호
• /
• pp.1-5
• /
• 2007

Solid dispersions of piroxicam were prepared by melting method using poloxamer as a carrier. The results of DSC and XRD studies showed that the amorphous farm of piroxicam coexisted with the crystalline form in the solid dispersions. However, the ratio of crystalline form of piroxicam in the solid dispersion prepared by melting method decreased in comparison with the same ratio of the solid dispersion prepared by solvent method. As the ratio of poloxamer in the solid dispersion increased, the ratio of the amorphous form of piroxicam in the solid dispersion increased. The dissolution rate of piroxicam from the solid dispersions was significantly higher than that from piroxicam powder. In comparison to the solid dispersion prepared by solvent method, the dissolution rate of piroxicam from the solid dispersion prepared by melting method was higher. As the ratio of poloxamer in the solid dispersion prepared by melting method increased, the initial dissolution rate decreased, however, the total amount dissolved at the end of the study increased.

• 대한약학회:학술대회논문집
• /
• 대한약학회 2002년도 Proceedings of the Convention of the Pharmaceutical Society of Korea Vol.2
• /
• pp.412.1-412.1
• /
• 2002

Purpose. To prepare PVP-based solid dispersions containing lovastatin (LOS) and solubilizers (sodium lauryl sulfate. Tween80. oleic acid) to enhance dissolution of practically insoluble LOS. Methods. Solid dispersions containing LOS were prepared by dissolving two different organic solvent systems (acetone/ethanol or acetonitrile/ethanol). Results. The stickiness and flowability of solid dispersion powders were dependent on the composition and ratio of the solubilizers. (omitted)

• 폴리머
• /
• 제35권4호
• /
• pp.277-283
• /
• 2011

고체분산체는 난용성 약물의 용출률 개선을 위한 방법으로 주로 사용된다. 난용성 약물인 프란루카스트를 플라스돈 S-630과 함께 분무건조하여 고체분산체를 제조하였다. pH에 따른 프란루카스트 용해도 실험을 실시하여 높은 pH에서 약물의 용해도가 높게 나왔다. 입도 분석으로 고체분산체 내의 약물의 크기가 나노 크기로 작아진 것을 확인하였다. 표면전위를 측정하여 고체분산체가 음전하를 가지고 있는 것을 확인하였다. 주사전자현미경으로 고체분산체의 표면이 구형임을 확인하였고, 시차주사열량계와 X-선 회절 분석법을 통해 고체분산체가 무정형임을 확인하였다. 고체분산체의 용출특성을 알아보기 위해 인공장액(pH 6.8)에서 용출거동을 확인하였고, 대조실험을 위해 시판제인 오논$^{(R)}$캡슐을 사용하였다. 이 결과로 분무건조를 통한 고체분산제의 제조를 통해 난용성 약물의 용출특성을 확인하였고, 경구용 약제학적 형태를 가질 수 있는 것을 확인하였다.

• Journal of Pharmaceutical Investigation
• /
• 제41권3호
• /
• pp.125-142
• /
• 2011

Solid dispersion, defined as the dispersion of one or more active ingredient in a carrier or matrix at solid state, is an efficient strategy for improving dissolution of poorly water-soluble drugs for enhancement of their bioavailability. Compared to other conventional formulations such as tablets or capsules, solid dispersion which can be prepared by various methods has many advantages. However, despite numerous studies which have been carried out, limitations for commercializing these products remain to be solved. For example, during the manufacturing process or storage, amorphous form of solid dispersion can be converted into crystalline form. That is, the dissolution rate of solid dispersion would continuously decrease during storage, resulting in a product of no value. To resolve these problems, studies have been conducted on the effects of excipients. In fact, modification of the solid dispersions to overcome these disadvantages has progressed from the first generation to the recent third generation products. In this review, an overview on solid dispersions in general will be given with emphasis on the various manufacturing processes which include the use of polymers and on the stabilization strategies which include methods to prevent crystallization.

• Journal of Pharmaceutical Investigation
• /
• 제19권2호
• /
• pp.109-116
• /
• 1989

Solid dispersion of fenticonazole nitrate (FN) with poloxamer 407, polyethylene glycol 6000, povidone (K-90) were prepared by the solvent method. To characterize the state of the drug in solid dispersions, the x-ray diffractometry and differential scanning calorimetry were carried out. The identification of these systems suggested that FN in the poloxamer 407 system remained in crystalline state, and the drug in the PVP system was amorphous. A marked increase in the dissolution rate of FN was attained by dispersing the drug in the hydrophilic polymers used, and the dispersion with poloxamer 407 was superior to the other two carriers in releasing the drug into solution.

• 약학회지
• /
• 제37권3호
• /
• pp.216-227
• /
• 1993

Complex formations of practically insoluble antelmintic drugs such as mebendazole (MBZ), albendazole (ABZ) and flubendazole (FBZ) with dimethyl-$\beta$-cyclodextrin (DM-$\beta$-CyD) and 2-hydroxypropyl-$\beta$-cyclodextrin (HP-$\beta$-CyD) together with $\alpha$-, $\beta$- and $\gamma$-cyclodextrins(CyDs) in duffered solutions were investigated by solubility method. $A_{L}$ type phase solubility diagrams were obtained in all cases except for the complexation (B$_{s}$, type) of FBZ with $\gamma$-CyD. The highest stability constants were obtained with DM-$\beta$-CyD, followed by $\alpha$-CyD > $\beta$-CyD > HP-$\beta$-CyD > $\gamma$-CyD for ABZ, and HP-$\beta$-CyD > $\gamma$-CyD > $\beta$-CyD > $\alpha$-CyD for FBZ at pH 1.2. On the other hand, solid dispersion systems of ABZ and FBZ with $\beta$- and DM-$\beta$-CyDs were prepared by solvent evaporation method and evaluated by dissolution, differential thermal analysis and powder x-ray diffractometry. The dissolution rates of ABZ- and FBZ-DM-$\beta$-CyD solid dispersions were much faster than those of drugs alone, corresponding physical mixtures and tablets on market both at pH 1.2 and 6.8. Although dissolution rates of all samples at pH 6.8 were by far lower than those obtained at pH 1.2, as explained by pH-solubility profiles for ABZ and FBZ, the dissolution rates at pH 6.8 of ABZ from $\beta$- and DM-$\beta$-CyD solid dispersions exceeded the respective equilibrium solubility (23.9 $\mu\textrm{g}$/ml). Fast dissolution of ABZ from solid dispersions with CyDs was attributed to the reduction of drug crystallinity and particle size which was supported by DTA and powder x-ray diffractometry. Consequently these results suggest that solid dispersion systems with CyDs may provide useful means to markedly enhance the solubility and dissolution of benzimidazole antelmintic drugs.

• 폴리머
• /
• 제36권1호
• /
• pp.41-46
• /
• 2012

본 연구에서는 대표적인 난용성 약물이며, 경구용 천식 치료제 중 하나인 pranlukast의 용해도 및 용출성 개선 제제 개발을 위해 친수성 고분자인 poly(ethylene glycol) (PEG)와 고분자 계면활성제인 poloxamer를 사용하여 열용융법(HM)과 용매증발법(SE)에 의한 고체분산체를 제조하였다. 고체분산체 내 약물의 결정성 변화를 DSC, PXRD로 분석한 결과, 약물의 결정성이 크게 감소하였고, 부분적으로 무정형으로 변화하였음을 확인하였다. 용출시험 및 용해도 분석결과, 고유 약물에 비해 용해도와 용출 속도가 크게 증가하였다. Pranlukast, PEG, poloxamer가 1:5:1의 조성으로 열용융법에 의해 제조된 고체분산체가 가장 우수한 용해도 및 용출속도 향상 결과를 보였다. 결과적으로 PEG과 poloxamer를 이용한 고체분산체 제제는 난용성 약물인 pranlukast의 용해도와 생체이용률을 개선하는데 유용하게 응용될 것으로 기대된다.

• Journal of Pharmaceutical Investigation
• /
• 제40권5호
• /
• pp.277-283
• /
• 2010

CoQ with low melting temperature was exploited to improve its solubility by preparing its solid dispersions (SDs) with a meltable polymer, poloxamer 407 (P 407). P407 can be utilized for a relatively simple, quick, inexpensive, reproducible and potentially scalable manner in the low temperature melting method. CoQ 10 solubility and dissolution increased with increasing concentrations of P 407 in SDs. Comparison of the enhanced dissolution of CoQ 10 from different poloxamers suggested that the preparation of CoQ 10 SDs using P 407 as a meltable hydrophilic polymer carrier could be a promising approach to improve its dissolution.